Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02828670
Other study ID # AUDIA APJ 2014
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 7, 2016
Est. completion date June 2023

Study information

Verified date June 2020
Source Centre Hospitalier Universitaire Dijon
Contact Sylvain AUDIA
Phone 3.80.29.34.32
Email sylvain.audia@chu-dijon.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

T follicular helper (TFH) cells represent a T cell subset dedicated to the activation of B cells. They have been involved in the pathogenesis of autoimmune diseases in humans such as lupus and Sjögren disease. We recently showed that TFH are implicated in the activation of autoreactive B lymphocytes during ITP. Autoimmune hemolytic anemia (AIHA) is an autoimmune disease due to antibodies targeting red blood cells. To date, the role of TFH in the pathogenesis of AIHA is not known. We hypothesize that AIHA is associated with an increase in the number and/or function of TFH, that could participate in the activation of autoreactive B lymphocytes.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 2023
Est. primary completion date June 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with a diagnosis of warm AIHA defined by - Hemoglobin <11 g/dl - Low haptoglobin level - Positive direct antiglobulin test (IgG or IgG + complement) - Reticulocyte count >120 G/L - Patients - naive to treatment for hemolytic anemia or a in relapse - Older than 18 years - Able to understand written and spoken French - Persons who have provided written consent Control population - Patients who have given consent - Patients over 18 years - Patients with cold agglutinin disease (progressive AIHA and different treatments of warm autoantibody AIHA) can be included as a sub-group of controls - Patients with non-auto-immune hemolytic anemia (constitutional of enzymatic origin, membrane-related,…) can be included as a sub-group of controls Exclusion Criteria: - Patients without national health insurance - Pregnancy or breast-feeding women - Adults under guardianship - Patients with cancer or malignant hemopathy - Patients with an on-going infection - Patients treated with corticoids or immunosuppressants

Study Design


Intervention

Biological:
blood sample

Procedure:
spleen sample


Locations

Country Name City State
France CHU Dijon Bourgogne Dijon

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary the proportion of circulating T follicular helper lymphocytes (TFH) in patients with Autoimmune Hemolytic Anemia (AIHA) and in control subjects. baseline
Primary the proportion of circulating TFH in patients with Autoimmune Hemolytic Anemia (AIHA), at diagnosis and after 3 months of treatment with steroids through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05057481 - Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus Phase 3
Recruiting NCT05937828 - OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
Recruiting NCT05263817 - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis Early Phase 1
Completed NCT03269292 - Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia
Recruiting NCT05694312 - Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL Phase 2
Completed NCT03538041 - A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia Phase 2
Recruiting NCT03918265 - Tacrolimus Treatment for Refractory Autoimmune Cytopenia Phase 4
Completed NCT02389231 - Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment Phase 1/Phase 2
Active, not recruiting NCT03576742 - Severe Immune Cytopenia Registry Www.Sic-reg.Org
Active, not recruiting NCT04657094 - Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia Phase 2
Recruiting NCT02877706 - French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Recruiting NCT05931718 - Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
Completed NCT02158195 - Immunopathology of Autoimmune Hemolytic Anemia
Completed NCT00001630 - Treatment of Autoimmune Thrombocytopenia (AITP) Phase 1
Withdrawn NCT04039477 - A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP Phase 2
Recruiting NCT04024202 - Data Registry of Auto Immune Hemolytic Anemia
Not yet recruiting NCT05711264 - Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia.
Completed NCT02689986 - Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease Phase 2
Recruiting NCT06212154 - CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy Phase 1
Completed NCT04057703 - Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.